zuclopenthixol acetate

**Zuclopenthixol acetate** is a typical antipsychotic neuroleptic of the thioxanthene class, used primarily for rapid control of acute psychosis and exacerbations of serious mental illnesses, such as schizophrenia and acute mania. It is formulated as a short-acting intramuscular depot injection, providing therapeutic effects for 2–3 days. It exerts its effect mainly by antagonism at dopamine D1 and D2 receptors, leading to antipsychotic, sedative, and anti-aggressive properties. Zuclopenthixol acetate is one of several formulations of zuclopenthixol, synthesized specifically to provide rapid but short-lived control of agitation or psychosis, particularly in inpatient settings where oral medication is not feasible. Major brand names include Clopixol Acuphase and Cisordinol Acutard. The compound was developed by Lundbeck in the mid-1980s[1][3][7].

Brand names

Clopixol AcuphaseCisordinol Acutard

Other names

(Z)-Clopenthixol acetate4-[(3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]piperazin-1-yl)ethanol acetate1-Piperazineethanol, 4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]-, acetate